A multicomponent serogroup B meningococcal vaccine is licensed for use in Europe: what do we know, and what are we yet to learn?

被引：44

作者：

Martin, Natalie G. ^{[1
,3
]}

Snape, Matthew D. ^{[2
,4
]}

机构：

[1] Univ Oxford, Dept Paediat, Oxford OX37LE, England

[2] Univ Oxford, Dept Paediat, NIHR Oxford Biomed Ctr, Oxford, England

[3] Univ Oxford, John Radcliffe Hosp, Dept Paediat, Oxford OX37LE, England

[4] Univ Oxford, NIHR Oxford Biomed Ctr, Dept Paediat, Oxford OX37LE, England

来源：

EXPERT REVIEW OF VACCINES | 2013年 / 12卷 / 08期

关键词：

immunogenicity; meningococcal; reactogenicity; safety; serogroup B; vaccine; MEMBRANE VESICLE VACCINE; H-BINDING-PROTEIN; C CONJUGATE VACCINE; KAWASAKI-DISEASE; NEW-ZEALAND; FEBRILE SEIZURES; INVESTIGATIONAL MULTICOMPONENT; BACTERICIDAL ACTIVITY; ANTIBODY PERSISTENCE; HEALTHY ADOLESCENTS;

D O I：

10.1586/14760584.2013.814862

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The first meningococcal vaccine with the potential to provide broad coverage against serogroup B disease has recently been approved for use in Europe. This vaccine, multi-component serogroup B vaccine (4CMenB), contains recombinant proteins and outer membrane vesicles, and has been extensively studied in clinical trials involving over 7500adults, children and infants. As well as demonstrating immunogenicity against a range of serogroup B meningococcal strains, these trials have also demonstrated relatively high rates of fever following infant immunization. This article will summarize the vaccine composition, clinical trials and suggested schedules of this vaccine, with specific attention to immunogenicity, reactogenicity, safety, potential coverage and optimal implementation of this vaccine.

引用

页码：837 / 858

页数：22

共 115 条

[1] Potential impact of the bivalent rLP2806 vaccine on Neisseria meningitidis carriage and invasive serogroup B disease [J].

Anderson, Annaliesa S. ;

Hao, Li ;

Jiang, Qin ;

Harris, Shannon L. ;

Jones, Thomas R. ;

Perez, John L. ;

York, Laura ;

Eiden, Joseph ;

Jansen, Kathrin U. .

HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2013, 9 (03) :471-479

[2] Post-licensure comparison of the safety profile of diphtheria/tetanus/whole cell pertussis/haemophilus influenza type b vaccine and a 5-in-1 diphtheria/tetanus/acellular pertussis/haemophilus influenza type b/polio vaccine in the United Kingdom [J].

Andrews, Nick ;

Stowe, Julia ;

Wise, Lesley ;

Miller, Elizabeth .

VACCINE, 2010, 28 (44) :7215-7220

[3]

[Anonymous], NIPH ANN

[4]

[Anonymous], NEW UND VACC IMPL

[5]

[Anonymous], 2010, NEISS MEN

[6]

[Anonymous], 2004, NEW VACC CHILDH IMM

[7]

[Anonymous], 18 INT PATH NEISS C

[8] Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus [J].

Bambini, Stefania ;

Muzzi, Alessandro ;

Olcen, Per ;

Rappuoli, Rino ;

Pizza, Mariagrazia ;

Comanducci, Maurizio .

VACCINE, 2009, 27 (21) :2794-2803

[9] Prevalence of factor H-binding protein variants and NadA among meningococcal group B isolates from the United States: Implications for the development of a multicomponent group B vaccine [J].

Beernink, Peter T. ;

Welsch, Jo Anne ;

Harrison, Lee H. ;

Leipus, Arunas ;

Kaplan, Sheldon L. ;

Granoff, Dan M. .

JOURNAL OF INFECTIOUS DISEASES, 2007, 195 (10) :1472-1479

[10] Rapid genetic grouping of factor H-binding protein (genome-derived neisserial antigen 1870), a promising group B meningococcal vaccine candidate [J].

Beernink, Peter T. ;

Leipus, Arunas ;

Granoff, Dan M. .

CLINICAL AND VACCINE IMMUNOLOGY, 2006, 13 (07) :758-763

← 1 2 3 4 5 6 7 8 9 10 →